ERT has announced the acquisition of APDM Wearable Technologies, a next-generation provider of wearables and digital biomarkers. The combined company will generate higher-fidelity and more powerful data to enable clinical trials to be more predictable, cost-effective, and efficient.
APDM’s wearable platform is designed to address clinical trial challenges by providing precision motion data collected with medical-grade wearable sensors and novel digital endpoints to guide critical decision-making and allow for more objective, efficient, and effective evaluation of therapies.
“We are thrilled that our advanced wearable platform will be added to ERT’s suite of proven eClinical technologies to help innovative clinical trial sponsors minimize uncertainty and risk in the development of CNS and movement disorder treatments, ultimately improving patients’ lives,” said Dr. Mateo Aboy, Co-Founder & Chairman of APDM.
“To truly understand a new drug’s effect on movement disorders, sponsors need objective, real-world data that can only be captured by a medical-grade precision motion device and combined with traditional clinical endpoints for a complete view on efficacy,” said James Corrigan, President, and CEO of ERT. “APDM’s advanced technology and broad understanding of objective precision movement measurement complements ERT’s expertise in high-quality clinical trial data collection, delivering the most efficient and effective approach for trial sponsors developing new medical treatments for the millions of patients living with movement disorders today.”